Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Trial Profile

A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camptothecin (Primary) ; Bevacizumab
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Cerulean Pharma
  • Most Recent Events

    • 11 Sep 2017 Results assessing safety and efficacy of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma, were published in the Annals of Oncology.
    • 17 Aug 2016 According to a Cerulean Pharma media release, the full data set from the trial are expected to be submitted for presentation at an upcoming medical conference.
    • 17 Aug 2016 Results published in Cerulean Pharma Inc media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top